| 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation. | |
| | |
MedLine Citation:
|
PMID: 20490488 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: This prospective multicentre study assesses the usefulness of FDG PET/CT in characterizing and making the therapeutic decision concerning adrenal tumours that are suspicious or indeterminate in nature after conventional examinations (CE). METHODS: Seventy-eight patients (37 men, 41 women, 81 adrenal lesions) underwent FDG PET/CT after CE including CT scan, biological tests and optionally (131)I-metaiodobenzylguanidine (MIBG) and/or (131)I-norcholesterol scans. FDG adrenal uptake exceeding that of the liver was considered positive. PET results were not decisive. Surgery was discussed when at least one of the following criteria was found during CE: size >3 cm, spontaneous attenuation value >10 HU, heterogeneous aspect, abnormal MIBG or norcholesterol scan or hormonal hypersecretion. RESULTS: Following the gold standard (histology analysis or >or=9 months follow-up), 49 lesions potentially qualified for surgery (malignant = 27, benign secreting = 22) and 32 benign non-secreting lesions did not. PET was negative in 97% of non-surgical lesions and positive in 73% of potentially surgical ones which included all the malignant lesions, except 3 renal cell metastases, and 12 of 22 benign secreting lesions. The negative predictive value for malignancy was 93% (41/44) and positive predictive value for detecting surgical lesions was 97% (36/37). A high FDG uptake (maximum standardized uptake value >or= 10) was highly predictive of malignancy. CONCLUSION: Adrenal FDG uptake is a good indicator of malignancy and/or of secreting lesions and should lead one to discuss surgery. If there is no prior history of poorly FDG-avid cancer, the absence of FDG uptake should avoid unnecessary removal of benign adrenal lesions. |
| | |
Authors:
|
Catherine Ansquer; Sonia Scigliano; Eric Mirallié; David Taïeb; Laurent Brunaud; Fredéric Sebag; Christophe Leux; Delphine Drui; Benoît Dupas; Karine Renaudin; Françoise Kraeber-Bodéré |
Related Documents
:
|
7457078 - Non traumatic cerebellar hematomas. 4064478 - The role of computed tomography in the assessment and treatment of acetabular fractures. 2942338 - Diagnosis of sacral perineural cysts by computed tomography. 19859858 - Computer-aided detection (cad) and assessment of malignant lesions in the liver and lun... 2753798 - Primary ovarian adenocarcinoma associated with teratomatous elements in a mare. 17328498 - Asteroid bodies in a lymph node aspirate. a case report. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study Date: 2010-05-19 |
Journal Detail:
|
Title: European journal of nuclear medicine and molecular imaging Volume: 37 ISSN: 1619-7089 ISO Abbreviation: Eur. J. Nucl. Med. Mol. Imaging Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-08-10 Completed Date: 2010-11-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101140988 Medline TA: Eur J Nucl Med Mol Imaging Country: Germany |
Other Details:
|
Languages: eng Pagination: 1669-78 Citation Subset: IM |
Affiliation:
|
Service de Médecine Nucléaire, CHU-Hôtel Dieu, Nantes, France. catherine.ansquer@chu-nantes.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenal Gland Neoplasms
/
diagnosis*,
radiography,
radionuclide imaging,
surgery* Adult Aged Aged, 80 and over Female Fluorodeoxyglucose F18 / diagnostic use* Humans Male Middle Aged Positron-Emission Tomography / methods* Prospective Studies Recurrence Tomography, X-Ray Computed / methods* Young Adult |
| Chemical | |
Reg. No./Substance:
|
63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Erratum to: Comparative genomic analysis of mammalian NKG2D ligand family genes provides insights in...
Next Document: Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma...